SPARC Reports Zero Deviation in Preferential Issue Utilization for Q2 FY26-27
Sun Pharma Advanced Research Company Ltd · Others (Uncategorized) · 03 Nov 2026, 1:41 am
SPARC Reports Zero Deviation in Preferential Issue Utilization for Q2 FY26-27 Acuité Ratings & Research issued a clean Monitoring Agency Report for Sun Pharma Advanced Research Company Ltd. for the quarter ended 30th Sep'26, confirming zero deviation from stated objects. Out of the total ₹599.98 Cr preferential warrant issue, ₹150.00 Cr raised earlier was fully utilized toward working capital loan repayment during Q1 FY26-27. No additional warrants were subscribed or funds received during Q2 FY26-27, leaving zero additional utilization during the quarter across R&D clinical trial activities (₹300.00 Cr allocated) and general corporate purposes (₹149.98 Cr allocated).
Original exchange filing (PDF)
More announcements from Sun Pharma Advanced Research Company Ltd
- Receipt of No- Objection Letters from the Stock Exchanges for Reclassification of Promoter Group · 12 Nov 2026
- Response of Clarification sought from BSE Limited · 11 Nov 2026
- The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 11 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2026. · 03 Nov 2026
- Sun Pharma Advanced Research Company Limited has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 02 Nov 2026
- To consider and approve the financial results for the quarter and half year ended September 30, 2026 · 02 Nov 2026
- Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited .... · 02 Nov 2026
